Citations

Clear

4847 citation(s) found for "Yu, Eric".

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
Stein, Eytan M. , Garcia‐Manero, Guillermo , Rizzieri, David A. , Tibes, Raoul , Jongen-Lavrenic, Mojca, Altman, Jessica K. , Thomson, Blythe, Blakemore, Stephen J. , Daigle, Scott R., Waters, Nigel J. , Suttle, A. Benjamin, Clawson, Alicia, Pollock, Roy M. , Krivtsov, Andrei V. , Armstrong, Scott A. , DiMartino, Jorge, Hedrick, Eric, Löwenberg, Bob , Tallman, Martin S. , Löwenberg, Bob , Berdeja, Jesús G. , Savona, Michael R.

Mayo Clinic

Blood | May 3, 2018 | Volume: 131 | Issue: 24 | Pages: 2661-2669

10.1182/blood-2017-12-818948 | PMID 29724899 Get It

Key Points Pinometostat demonstrates first evidence of DOT1L target inhibition and clinical responses in a subset of MLL-r advanced leukemia patients. The observed safety profile of pinometostat shows potential for exploration of combination therapies in leukemia.
Bleeding after Percutaneous Transhepatic Biliary Drainage: Incidence, Causes and Treatments
Quencer, Keith , Tadros, Anthony , Marashi, Keyan B, Cizman, Ziga , O’Hara, Ryan , Öklü, Rahmi , Quencer, Keith B , Oklu, Rahmi , Reiner, Eric J.

Mayo Clinic

Journal of Clinical Medicine | May 3, 2018 | Volume: 7 | Issue: 5 | Pages: 94

10.3390/jcm7050094 | PMID 29723964 Get It

Of all procedures in interventional radiology, percutaneous transhepatic biliary drainage (PTBD) is amongst the most technically challenging. Successful placement requires a high level of assorted skills. While this procedure can be life-saving, it can also lead to significant iatrogenic harm, often manifesting as bleeding. Readers of this article will come to understand the pathophysiology and anatomy underlying post-PTBD bleeding, its incidence, its varied clinical manifestations and its initial management. Additionally, a structured approach to its treatment emphasizing endovascular and percutaneous methods is given.
A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)
Schafer, Eric S. , Rau, Rachel E. , Liu, Xiaowei , D’Adamo, David R., Scott, Rachael , Reyderman, Larisa, Martinez, Gresel, Devarajan, Sandhya, Fox, Elizabeth , Weigel, Brenda J. , Blaney, Susan M. , Reid, Joel M. , Schafer, Eric S , Berg, Stacey L. , Minard, Charles G.

Mayo Clinic

Pediatric Blood & Cancer | May 2, 2018 | Volume: 65 | Issue: 8 | Pages: No page available

10.1002/pbc.27066 | PMID 29719113 Get It

Abstract Background Eribulin mesylate is a novel anticancer agent that inhibits microtubule growth, without effects on shortening, and promotes nonproductive tubulin aggregate formation. We performed a phase 1 trial to determine the dose‐limiting toxicities (DLTs), maximum tolerated or recommended phase 2 dose (MTD/RP2D), and pharmacokinetics (PK) of eribulin in children with refractory or recurrent solid (excluding central nervous system) tumors. Methods Eribulin was administered intravenously on days 1 and 8 in 21‐day cycles. Three dose levels (1.1, 1.4, and 1.8 mg/m 2 /dose) were evaluated using the rolling six design with additional patients enrolled into a PK expansion cohort at the MTD. PK samples were obtained following the day 1, cycle 1 dose. Results Twenty‐three patients, ages 3–17 (median 14) years were enrolled; 20 were evaluable for toxicity. DLTs occurred in 0/6 and 1/6 subjects at the 1.1 and 1.4 mg/m 2 /dose, respectively. One subject at the 1.4 mg/m 2 /dose had grade 4 neutropenia and grade 3 fatigue. At the 1.8 mg/m 2 /dose, 2/5 subjects experienced dose‐limiting (grade 4) neutropenia. Grade 3/4 non‐DLTs included lymphopenia and hypokalemia, while low‐grade toxicities included anorexia and nausea. No episodes of grade > 2 corrected QT interval prolongation or peripheral neuropathy were reported. Eribulin pharmacokinetic parameters were highly variable; the median elimination half‐life was 39.6 (range 24.2–96.4) hr. A partial response was observed in one patient (Ewing sarcoma). Conclusions Eribulin was well tolerated in children with refractory or recurrent solid tumors with neutropenia identified as the primary DLT. The RP2D of eribulin is 1.4 mg/m 2 /dose on days 1 and 8 of a 21‐day cycle.
Conservation of Mannan Synthesis in Fungi of the Zygomycota and Ascomycota Reveals a Broad Diagnostic Target
Burnham‐Marusich, Amanda R. , Hubbard, Breeana, Kvam, Alexander J., Gates‐Hollingsworth, Marcellene A., Green, Heather R. , Soukup, Eric, Kozel, Thomas R. , Limper, Andrew H.

Mayo Clinic

mSphere | May 1, 2018 | Volume: 3 | Issue: 3 | Pages: No page available

10.1128/msphere.00094-18 | PMID 29720523 Get It

A key question asked when faced with an infection, an infestation, or environmental damage is whether it is a fungus. Identification of fungi as the cause of the problem can lead to remediation or treatment. Zygomycetes and ascomycetes account for the vast majority of fungal causes of human, animal, and plant disease, large-scale biodiversity loss, agricultural spoilage, and contamination of water-damaged buildings. These studies revealed the conservation of a common cell wall structural component of zygomycetes and ascomycetes to be a diagnostic target applicable to multiple pathogenic fungi and have leveraged that insight for practical use. Monoclonal antibodies reactive with this pan-fungal structure were produced and used to construct immunoassays (including ELISA and lateral flow assay) for detection of a broad range of pathogenic fungi.
Teaching Video NeuroImages: Acquired focal neuromyotonia in LGI-1 autoimmunity
López‐Chiriboga, A. Sebastian , Matsumoto, Joseph Y., Sorenson, Eric J. , Matsumoto, Joseph, Sorenson, Eric, Klein, Christopher J. , McKeon, Andrew

Mayo Clinic

Neurology | April 30, 2018 | Volume: 90 | Issue: 18 | Pages: No page available

10.1212/wnl.0000000000005426 | PMID 29712816 Get It

Novel Common Genetic Susceptibility Loci for Colorectal Cancer
Schmit, Stephanie L. , Edlund, Christopher K., Schumacher, Fredrick R. , Harrison, Tabitha A. , Huyghe, Jeroen R. , Qu, Chenxu, Melas, Marilena , Berg, David Van Den , Wang, Hansong, Tring, Stephanie, Plummer, Sarah J. , Alonso, M. Henar , Anton, Kristen , Aragaki, Aaron K. , Arndt, Volker , Barry, Elizabeth L. , Berndt, Sonja I. , Bloomer, Amanda M. , Boehm, Juergen , Brenner, Hermann , Brezina, Stefanie , Buchanan, Daniel D. , Butterbach, Katja, Caan, Bette J. , Carlson, Christopher S. , Castelao, Jose E. , Chang‐Claude, Jenny , Cheng, Ya‐Wen , Chin, Lee Soo, Church, Timothy R. , Correa, Marcia Cruz, Curtis, Keith R. , Duggan, David , Easton, Douglas F. , English, Dallas R. , Fischer, Rocky, Fritsche, Lars G. , Fuchs, Charles S. , Gago-Domínguez, Manuela , Gala, Manish , Gallinger, Steven , Gauderman, W. James, Giovannucci, Edward L. , Gogarten, Stephanie M. , González‐Villalpando, Clicerio, Gonzalez-Villalpando, Elena M., Greenson, Joel K. , Gsur, Andrea , Gunter, Marc J. , Haiman, Christopher A. , Hampe, Jochen , Harlid, Sophia , Harju, John F., Hayes, Richard B. , Hofer, Philipp , Hoffmeister, Michael , Huang, Shu-Chen, Huerta, José María , Hunter, David J., Idos, Gregory , Jackson, Rebecca D. , Jacobs, Eric J. , Jee, Sun Ha , Jenkins, Mark A. , Jia, Wei-Hua , Jiao, Shuo , Joshi, Amit D. , Kolonel, Laurence N. , Kono, Suminori , Krogh, Vittorio , Küehn, Tilman, Küry, Sébastien , LaCroix, Andrea Z. , Laurie, Cecelia , Lejbkowicz, Flavio, Lemire, Mathieu , Lenz, Heinz‐Josef , Levine, David , Li, Li , Lindor, Noralane M. , Liu, Yun-Ru, Lu, Yingchang , Luh, Frank , Ma, Jing , Mancao, Christoph , Manion, Frank J. , Markowitz, Sanford D. , Martín, Vicente , Matsuo, Keitaro , McDonnell, Kevin , McNeil, Caroline E, Murphy, Neil , Offit, Kenneth, Omichessan, Hanane , Cotoré, Jesús Paredes, Pérez‐Mayoral, Julyann, Rennert, Gad , Rennert, Hedy S., Riggs, Bridget M., Schafmayer, Clemens, Sellers, Thomas A. , Seminara, Daniela, Shibata, David , Siegel, Erin M. , Slattery, Martha L. , Stintzing, Sebastian , Taverna, Darin, Thibodeau, Stephen N. , Thomas, Duncan C. , Trichopoulou, Antonia , Duijnhoven, Fränzel J.B. van , Guelpan, Bethany van, Virtamo, Jarmo, Weinstein, Stephanie J. , Win, Aung Ko , Woods, Michael O. , Wu, Anna H. , Wu, Kana , Xiang, Yong-Bing , Zanke, Brent W., Zeng, Yi-Xin , Zhang, Ben , Zubair, Niha, Figueiredo, Jane C. , Lindblom, Annika , Moreno, Vı́ctor , Peters, Ulrike , Conti, David V. , Gruber, Stephen B. , Kühn, Tilman , Buchanan, Daniel D , Win, Aung K , Rennert, Gad , Hoffmeister, Michael , Arndt, Volker , English, Dallas R , Martín, Vicente , Moreno, Victor , Gunter, Marc J , Jenkins, Mark A , Van Den Berg, David J , Harrison, Tabitha A , Matsuo, Keitaro , Kury, Sebastien , Brenner, Hermann , Gago-Dominguez, Manuela , Hampe, Jochen , Murphy, Neil , Hayes, Richard B , Brezina, Stefanie , Conti, David V , Gong, Jian Feng , Albanes, Demetrius , Amos, Christopher I. , Bezieau, Stéphane , Bien, Stephanie A. , Boutron‐Ruault, Marie‐Christine , Campbell, Peter T. , Chan, Andrew T. , Chanock, Stephen Jacob , Cheng, Iona C. , Church, James M. , Coetzee, Gerhard A. , Cotterchio, Michelle , Feskens, Edith J. M. , FitzGerald, Liesel M. , Fortini, Barbara K. , Giles, Graham G. , Grady, William M. , Hopper, John L. , Hudson, Thomas J , Iwasaki, Motoki , Kooperberg, Charles , Li, Christopher I , Lieb, Wolfgang , Lin, Yi , Liu, Yun‐Ru , Loupakis, Fotios , Matsuda, Koichi , McNeil, Caroline E, Milne, Roger L. , Molina, Antonio José , Mukherjee, Bhramar , Newcomb, Polly A. , Palli, Domenico , Pharoah, Paul D.P. , Potter, John D. , Qu, Conghui , Raskin, Leon , Schoen, Robert E. , Severi, Gianluca , Shi, Wei , Shu, Xiao‐Ou , Southey, Melissa C. , Stadler, Zsofia , Stern, Mariana Carla , Tsugane, Shoichiro , Ulrich, Cornelia M. , Vijai, Joseph , White, Emily E. , Wolk, Alicja , Yen, Yun , Kweon, Sun-Seog , Zheng, Wei , Marchand, Loı̈c Le , Casey, Graham , Church, Timothy R , Caan, Bette J , Lindblom, Annika

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 30, 2018 | Volume: 111 | Issue: 2 | Pages: 146-157

10.1093/jnci/djy099 | PMID 29917119 Get It

Abstract Background Previous genome-wide association studies (GWAS) have identified 42 loci (P < 5 × 10−8) associated with risk of colorectal cancer (CRC). Expanded consortium efforts facilitating the discovery of additional susceptibility loci may capture unexplained familial risk. Methods We conducted a GWAS in European descent CRC cases and control subjects using a discovery–replication design, followed by examination of novel findings in a multiethnic sample (cumulative n = 163 315). In the discovery stage (36 948 case subjects/30 864 control subjects), we identified genetic variants with a minor allele frequency of 1% or greater associated with risk of CRC using logistic regression followed by a fixed-effects inverse variance weighted meta-analysis. All novel independent variants reaching genome-wide statistical significance (two-sided P < 5 × 10−8) were tested for replication in separate European ancestry samples (12 952 case subjects/48 383 control subjects). Next, we examined the generalizability of discovered variants in East Asians, African Americans, and Hispanics (12 085 case subjects/22 083 control subjects). Finally, we examined the contributions of novel risk variants to familial relative risk and examined the prediction capabilities of a polygenic risk score. All statistical tests were two-sided. Results The discovery GWAS identified 11 variants associated with CRC at P < 5 × 10−8, of which nine (at 4q22.2/5p15.33/5p13.1/6p21.31/6p12.1/10q11.23/12q24.21/16q24.1/20q13.13) independently replicated at a P value of less than .05. Multiethnic follow-up supported the generalizability of discovery findings. These results demonstrated a 14.7% increase in familial relative risk explained by common risk alleles from 10.3% (95% confidence interval [CI] = 7.9% to 13.7%; known variants) to 11.9% (95% CI = 9.2% to 15.5%; known and novel variants). A polygenic risk score identified 4.3% of the population at an odds ratio for developing CRC of at least 2.0. Conclusions This study provides insight into the architecture of common genetic variation contributing to CRC etiology and improves risk prediction for individualized screening.
Psychotherapy with Physically Disabled Patients
Oliveira, Rui Aragão , Milliner, Eric K., Page, Richard C.

Mayo Clinic

American Journal of Psychotherapy | April 30, 2018 | Volume: 58 | Issue: 4 | Pages: 430-441

10.1176/appi.psychotherapy.2004.58.4.430 | PMID 15807087 Get It

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
LaCasce, Ann S. , Bociek, R. Gregory , Sawas, Ahmed , Caimi, Paolo, Agura, Edward, Matous, Jeffrey, Ansell, Stephen M. , Crosswell, Howland E. , Islas‐Ohlmayer, Miguel, Behler, Caroline, Cheung, Eric, Forero‐Torres, Andres , O’Connor, Owen A. , Josephson, Neil C. , Advani, Ranjana H. , Advani, Ranjana H , Vose, Julie M. , Wang, Yinghui

Mayo Clinic

Blood | April 27, 2018 | Volume: 132 | Issue: 1 | Pages: 40-48

10.1182/blood-2017-11-815183 | PMID 29703778 Get It

Key PointsThe outpatient BV and bendamustine regimen is highly active as first salvage therapy in relapsed/refractory HL, with manageable toxicity. The CR rate of 73.6% exceeded those reported for standard chemotherapy regimens, and post-ASCT outcomes generally appeared excellent.
1059 Sleep Medicine as a Career Choice in US Residency Programs
Meinen, Candace, Junna, Mithri R. , Olson, Eric J.

Mayo Clinic

Sleep | April 27, 2018 | Volume: 41 | Issue: suppl_1 | Pages: A394-A394

10.1093/sleep/zsy061.1058 Get It

1080 The Collaborative Care Visit Model: A New Way to Provide Ongoing Care Targeted to Long-Term Stable Positive Airway Pressure Users
Moore, Wendy , Burr, L E, McNamara, Sara, Clark, Peter, Peine, N A, Finstuen, Thomas, Herold, Daniel L., Brown, Vicki, Warner, Christopher H. , Trapp, Gerald, Olson, Eric J. , Auger, R. Robert , Louis, Erik K. St. , Junna, Mithri R. , St Louis, E K , Herold, Daniel L. , Lipford, Melissa C.

Mayo Clinic

Sleep | April 27, 2018 | Volume: 41 | Issue: suppl_1 | Pages: A401-A401

10.1093/sleep/zsy061.1079 Get It